Objectives: The availability of antimicrobials that may be used for the treatment of infections caused by Neisseria gonorrhoeae has been limited by the emergence of antimicrobial resistance, particularly fluoroquinolone resistance. Few data exist regarding the pharmacodynamics of fluoroquinolone resistance selection in N. gonorrhoeae.
Introduction
Few available antimicrobials are recommended for the treatment of infections caused by Neisseria gonorrhoeae. The fluoroquinolones constitute a potential option for the treatment of gonococcal infections, but the use of these agents has been limited by the proliferation of fluoroquinolone-resistant N. gonorrhoeae (QRNG). The prevalence of QRNG (as measured by ciprofloxacin susceptibility) was found to have increased from 0% in 1990 to 14 .4% in 2003 in one multicentre surveillance study. 1 Infection with QRNG strains has been associated with men who have sex with men, ethnicity and recent antimicrobial use. 2, 3 QRNG was associated with fluoroquinolone treatment failure in a randomized trial comparing ciprofloxacin and cefixime, one of the current agents of choice for gonococcal infections. 4 Amidst concerns regarding the trend of increasing fluoroquinolone resistance in N. gonorrhoeae, the CDC removed the fluoroquinolones from the list of recommended treatment options in 2006. 5 Alternative antimicrobials that are recommended include ceftriaxone, cefixime and azithromycin. However, resistance to these agents, while rare, has been noted. 1, 6 Furthermore, the availability of cefixime has been inconsistent of late, and the CDC has recommended that azithromycin be used judiciously in the management of gonococcal infections because of the risk of promoting resistance with continued use.
Limited susceptibility studies support the efficacy of moxifloxacin against N. gonorrhoeae, although this fluoroquinolone has not been approved for the treatment of gonococcal infections. 7 -9 Moxifloxacin exhibited MIC values comparable to those of ciprofloxacin, gemifloxacin, levofloxacin and trovafloxacin for four N. gonorrhoeae isolates, including nalidixic acidresistant and -susceptible strains. 7 In another study, MIC 90 values of ciprofloxacin, levofloxacin, gatifloxacin and moxifloxacin for 87 isolates were .8 mg/L, .8 mg/L, 4 mg/L and 2 mg/L, respectively. 8 However, moxifloxacin has also been shown to exhibit only marginally superior activity against fluoroquinolone-resistant isolates. 9 Moxifloxacin, by virtue of its C-8-methoxy substituent, has been shown to restrict the development of fluoroquinolone resistance in other microorganisms. 10 Given the relative lack of antimicrobials that may be used in the therapy of N. gonorrhoeae, it is important to determine whether pharmacodynamic principles may be used to re-establish the fluoroquinolones as suitable therapeutic options. In particular, it is possible that revised fluoroquinolone dosing regimens may retain efficacy against QRNG, or that a particular fluoroquinolone is less likely to induce resistance in N. gonorrhoeae and/or displays enhanced activity against QRNG.
The mutant prevention concentration (MPC) is a susceptibility parameter that has been proposed as a substitute for the MIC as a measure of antimicrobial activity. 11 The MPC is defined as the MIC of the most resistant first-step mutant contained within a heterogeneous bacterial population and is measured as the lowest concentration that inhibits mutant growth when a large bacterial inoculum ($10 10 cfu/mL) is exposed to an antimicrobial. 12 Maintenance of antimicrobial concentrations above the MPC will theoretically prevent the selection of resistant organisms, while concentrations that are maintained in the range between the MIC and MPC [the mutant selection window (MSW)] are thought to promote the selection of resistant subpopulations. 13 Thus, the MPC may be used to more accurately assess the risk of resistance induction by antimicrobials than does the MIC. Using published pharmacokinetic parameters, comparisons of fluoroquinolones have been performed for organisms such as Streptococcus pneumoniae, where a hierarchy of agents was established based on the time each would attain supra-MPC concentrations.
14 No published work has evaluated the applicability of the MPC to the treatment of infections caused by N. gonorrhoeae.
We determined MPCs of ciprofloxacin, levofloxacin and moxifloxacin for wild-type and mutant N. gonorrhoeae and analysed the pharmacodynamics of these agents with respect to the MSW in order to determine whether a particular fluoroquinolone may be less likely to induce resistance in this pathogen, and whether use of multiple-dose fluoroquinolone regimens will serve to provide superior activity against N. gonorrhoeae. Analysis of the quinolone-resistance-determining region of gyrA in this mutant was performed using primers and PCR parameters described by Tanaka et al. 15 Nucleotide sequencing was performed using dideoxy chain termination, using the Applied Biosystems (ABI) 16 capillary 3130XL system. 16 Sequence analysis was performed using DS Gene 2.0 (Accelrys, Inc., San Diego, CA, USA).
Materials and methods

Microorganisms
Antimicrobial agents
Ciprofloxacin and levofloxacin were obtained from Sigma Chemical Company (St Louis, MO, USA). Moxifloxacin was obtained from Bayer Pharmaceuticals (Wayne, NJ, USA). Stock solutions of each analytical-grade powder in sterile water were freshly prepared on the day of each use.
Medium
All susceptibility (MIC, MPC) testing was performed using gonococcal (GC) agar (Difco Laboratories, Detroit, MI, USA) supplemented with 1% IsoVitaleX enrichment (Becton, Dickinson and Co., Franklin Lakes, NJ, USA). Bacterial inocula for MPC testing were prepared in gonococcal broth supplemented with 1% IsoVitaleX, prepared as described by Shapiro et al.
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MIC testing
MICs were determined using the Etest methodology (AB Biodisk, Solna, Sweden) with an inoculum of 5Â10 5 cfu/mL according to CLSI guidelines. 18 MICs were determined after incubation for 24 h at 35ºC in 5% CO 2 .
MPC determinations
The procedure described by Blondeau et al.
14 was used for MPC testing. Each isolate was inoculated on 10 plates of supplemented GC agar with a sterile cotton swab. After incubation for 24 h at 358C in 5% CO 2 , a confluent lawn of growth was obtained on each plate. All bacterial growth from these 10 plates was then transferred to 500 mL of supplemented GC broth and incubated for an additional 24 h at 358C in 5% CO 2 . The resulting suspension was centrifuged (5000 g for 30 min), supernatant was discarded and bacterial pellets were resuspended in supplemented GC broth to yield a concentration of 10 10 cfu/mL. Finally, 100 mL of this suspension was applied to each of 10 plates containing supplemented GC agar impregnated with known concentrations (2-fold stepwise dilutions) of each fluoroquinolone. Inoculated plates were incubated for 96 h at 358C in 5% CO 2 and screened visually for growth. The MPC was recorded as the lowest fluoroquinolone concentration that completely inhibited growth. MIC testing of resistant subpopulations was used to confirm MPC values and all MPC determinations were performed in duplicate. 
MSW-derived pharmacodynamic calculations
Pharmacodynamic analysis
MSW-related pharmacodynamic parameters (AUC/MPC, %T MSW and %T .MPC) are shown in Table 2 . Against ATCC 49226, all of the tested fluoroquinolones are predicted to attain supra-MPC concentrations for the entirety of each agent's dosage interval, whether administered as a single dose or as part of a multiple-dose regimen. However, the only fluoroquinolone that is predicted to attain concentrations above the MPC for m-49226 is moxifloxacin (%T .MPC¼ 100% for both singledose and multiple-dose regimens). Administration of levofloxacin is predicted to achieve %T MSW values of 43.15% and 37.45% in single-dose and multiple-dose regimens, respectively, against m-49226, while %T MSW values for ciprofloxacin against m-49226 are 100%, regardless of the dosage regimen. Predicted AUC/MPC values range from 2.03 (ciprofloxacin single-dose regimen against m-49226) to 613.76 (ciprofloxacin multipledose regimen against ATCC 49226).
Discussion
Few published data examining fluoroquinolone resistance selection in N. gonorrhoeae exist.
Ruiz et al. 7 exposed nalidixic acid-susceptible and -resistant isolates to the fluoroquinolones ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin and trovafloxacin, and determined spontaneous single-step mutation rates for each agent. Mutants growing in the presence of supra-MIC concentrations were obtained for all fluoroquinolones, with the exception of gemifloxacin. However, moxifloxacin exposure resulted in isolation of mutants less frequently than did exposure to ciprofloxacin, levofloxacin or trovafloxacin. The 8-methoxy fluoroquinolone gatifloxacin was found to possess lower MIC values, compared with ciprofloxacin, levofloxacin and ofloxacin, for ciprofloxacin-susceptible and -resistant N. gonorrhoeae. 21 In the study by Fung-Tomc et al., 21 gatifloxacin was found to exhibit a lesser propensity to select resistant derivatives of methicillin-resistant Staphylococcus aureus and S. pneumoniae, although resistance selection in N. gonorrhoeae was not examined. Ours is the first study to our knowledge to evaluate MPC values for N. gonorrhoeae. The relationship between fluoroquinolone concentrations, the MPC/MSW and restriction of resistant mutant outgrowth has been extensively studied. However, the effects of concentrations within the MSW and above the MPC have not been conclusively established, and it is unclear what degree of exposure relative to the MSW is necessary to prevent resistance development. Furthermore, the MPC-targeted pharmacodynamic parameter (e.g. C max /MPC, AUC/MPC, %T MSW and %T .MPC) that best predicts resistance restriction is unknown, with published studies finding that multiple parameters may correlate with resistance prevention. In studies that have sought to determine a correlation between one or more MPC-based pharmacodynamic parameters and the emergence of resistance, resistance selection has been variably associated with the parameters AUC/MPC, %T MSW , C max /MPC, AUC MSW (the area under the curve between the MIC and MPC) and %T. MPC. 22 -34 In a study of fluoroquinolone resistance in Escherichia coli, resistance selection correlated with AUC/MPC, but not %T MSW . 30 A second study of E. coli found that an AUC/MPC of 35 prevented selection of a single first-step fluoroquinolone mutant, while an AUC/MPC of 14 restricted selection of a double mutant; %T MSW as a predictor of resistance was not assessed. 31 Cui et al. 24 found that the emergence of levofloxacin resistance in rabbits infected with S. aureus was predicted by AUC/MPC, C max /MPC and %T. MPC. Emergence of gatifloxacin-resistant subpopulations of S. pneumoniae in vitro was predicted by %T MSW and AUC MSW , while another study of fluoroquinolone resistance in S. pneumoniae found that AUC/MPC and C max /MPC correlated with resistance selection. 28 Several in vitro analyses have particularly examined the effect of variable %T MSW values on outgrowth of resistant subpopulations. Against S. aureus, levofloxacin regimens attaining %T MSW values of 46.1% -57.5% selected resistant subpopulations, whereas %T MSW values of 19.6% -45.9% were not associated with resistance emergence. 32 In contrast, ciprofloxacin %T MSW values of 63.2% -99.8% were associated with the greatest losses in susceptibility in methicillin-resistant S. aureus, while %T MSW values between 50.4% and 67.6% variably selected for resistant subpopulations. 33 Several in vitro studies of fluoroquinolone resistance in S. aureus and S. pneumoniae have shown that resistance did not arise when %T MSW was less than 20% or 25%. 25 -27,29 However, in a study of ciprofloxacin against S. aureus, while %T MSW correlated with the enrichment of resistant mutants, such enrichment was more pronounced when ciprofloxacin concentrations were closer to the MIC (lower limit of the MSW), supporting the idea that placement of concentrations within the MSW may be an additional factor in resistance prevention and that resistance may be prevented by concentrations that are within the MSW, but near its upper boundary.
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In summary, the relationship between antimicrobial concentration, MPC or MSW and resistance selection appears to be a complex one. This complexity precludes definitive conclusions regarding the likelihood that fluoroquinolone resistance enrichment in N. gonorrhoeae may be prevented through preferential use of one or more agents, especially in the face of the documented development of fluoroquinolone resistance in this organism. However, we were able to establish a clear hierarchy of fluoroquinolone activity against mutant N. gonorrhoeae, with moxifloxacin exhibiting the most favourable pharmacodynamics with respect to the MSW. In contrast, all the fluoroquinolones tested are predicted to attain supra-MPC concentrations for the duration of the dosage interval against wild-type N. gonorrhoeae and so selection of single-step mutants in wild-type N. gonorrhoeae would not be predicted.
That QRNG developed at all might be considered somewhat unexpected, especially in light of our findings that fluoroquinolone concentrations should be maintained above the MSW for at least 20 h against wild-type N. gonorrhoeae (although concentrations must inevitably pass through the MSW upon cessation of therapy). It is possible that single-dose fluoroquinolone regimens failed in many instances to fully eradicate N. gonorrhoeae, despite clinical cure, and that repeated fluoroquinolone exposures led to eventual selection of resistant subpopulations. Furthermore, our data suggest that amplification of resistant mutants would occur more readily once first-step mutants emerged and were disseminated in the community.
Our data show that use of multiple-dose fluoroquinolone regimens may be a means to limit outgrowth of fluoroquinoloneresistant mutants, especially against pre-existing single-step mutant strains. Other in vitro studies have shown that a variable minimum value of AUC/MPC is required to prevent resistance emergence and that higher values lead to enhanced resistance restriction. Our data show that the magnitude of AUC/MPC would be increased by the use of multiple-dose regimens, with AUC/MPC increases from 2.03 to 4.80 (ciprofloxacin), 37.54 to 46.82 (levofloxacin) and 86.64 to 115.20 (moxifloxacin) attainable against m-49226. Furthermore, the %T MSW for levofloxacin against m-49226 would be reduced from 43.15% to 37.45% with use of a multiple-dose regimen; %T MSW values for moxifloxacin (0%) and ciprofloxacin (100%) would be unchanged by the use of multiple doses against the tested isolates.
A limitation of this study is the number of isolates tested and careful extrapolation of these results to other N. gonorrhoeae strains is warranted. However, the results obtained in this study with respect to the ratio of MPC to MIC are consistent with previous results obtained for a variety of microorganisms.
In conclusion, moxifloxacin is predicted to be less likely than either ciprofloxacin or levofloxacin to induce further fluoroquinolone resistance in mutant N. gonorrhoeae. In light of the limited number of antimicrobials available for the treatment of gonococcal infections, evaluation of the use of moxifloxacin for these infections may be warranted, although use of any fluoroquinolone against N. gonorrhoeae must necessarily be done with caution considering present resistance rates. Furthermore, use of fluoroquinolone regimens that incorporate multiple doses, rather than the historical practice of single-dose therapy, may help to prevent further fluoroquinolone resistance in N. gonorrhoeae. In vitro and animal models are necessary to confirm these predictions.
